Is Botulinum Toxin Type A Safe?

Botulinum toxin type A has an established role in therapeutic and aesthetic medicine, but its safety cannot be summarized simply as “safe” or “unsafe.”

The relevant question is whether a particular product has an acceptable benefit-risk profile when used in an appropriate patient, indication, dose, anatomical location and treatment protocol.

Safety can be influenced by:

• the specific BoNT-A product;

• indication;

• total dose and dose distribution;

• injection site;

• anatomy;

• administration technique;

• underlying medical conditions;

• concomitant medications; and

• previous exposure to botulinum toxin.

Clinical trials and systematic reviews provide important safety information, but current product-specific labeling remains the primary source for contraindications, warnings and precautions.

Why Safety Must Be Interpreted in Context

An adverse-event percentage has little meaning without knowing the clinical setting in which it was measured.

For example, treatment of glabellar lines uses different muscles, treatment goals and dosing patterns from treatment of post-stroke spasticity.

Likewise, eyelid ptosis is particularly relevant when treating facial areas around the eyes, whereas therapeutic studies involving larger limb muscles may evaluate a different spectrum of adverse events.

Therefore, safety data from one indication should not automatically be transferred to another.

What Do Systematic Reviews Show About Aesthetic BoNT-A Safety?

A systematic review by Cavallini and colleagues evaluated 35 clinical studies involving 8,787 participants treated in aesthetic settings. [1]

The review reported treatment-related events including:

blepharoptosis: 2.5%

brow ptosis: 3.1%

eye sensory disorders: 3.0%

in upper-face treatments, while lip asymmetries or imbalances were reported in lower-face treatment.

The reported events resolved spontaneously in the reviewed studies. [1]

A later meta-analysis of randomized, double-blind, placebo-controlled facial-rejuvenation trials also found that BoNT-A treatment was associated with a higher overall adverse-event rate than placebo, with events such as headache, eyelid ptosis and heavy eyelids contributing to the difference in some treatment areas. [2]

These findings support a more precise interpretation than simply calling aesthetic BoNT-A “risk-free.”

What Types of Adverse Events Can Occur?

Adverse events may broadly arise from several mechanisms.

Injection-Related Events

The injection procedure itself can be associated with:

• pain or tenderness;

• bruising or ecchymosis;

• swelling;

• erythema; and

• local discomfort.

These events are not necessarily caused by the pharmacologic action of BoNT-A itself.

Local Pharmacologic Effects

Because BoNT-A reduces cholinergic signaling and muscle activity, excessive weakening of the intended muscle or unintended effects on nearby muscles may produce clinically relevant events.

Depending on the anatomical region, examples may include:

• eyelid or brow ptosis;

• facial asymmetry;

• unwanted weakness;

• changes in local muscle function; or

• functional effects related to adjacent muscles.

The exact adverse-event profile depends strongly on the anatomical area and indication.

Effects Beyond the Intended Target

Product labeling for BoNT-A products may contain warnings regarding effects consistent with toxin action occurring beyond the intended injection area.

Potential manifestations described in BoNT-A safety labeling can include generalized muscle weakness and difficulties involving swallowing, speech or breathing.

These are clinically important warnings and should be taken from the current approved labeling of the specific product rather than generalized from one brand to another.

Why Does Anatomy Matter?

BoNT-A is intended to produce a pharmacologic effect in selected muscles.

The therapeutic target is therefore closely linked to anatomy.

An injection placed too close to a muscle that should remain active, or an unintended effect on adjacent muscles, can alter the clinical result and may produce an adverse effect.

This is especially relevant in anatomically compact regions such as the upper face, where small differences in muscle targeting may have visible or functional consequences.

Appropriate anatomical knowledge is therefore part of safety management.

Why Do Dose and Injection Technique Matter?

The clinical effect of BoNT-A depends partly on the amount administered and where it is placed.

Dose distribution, dilution or reconstitution, injection depth, injection location and selection of target muscles can all influence treatment.

This is why clinical-trial safety results must be interpreted together with the protocol used in that trial.

A favorable safety finding with one dose and injection pattern does not prove that every other dosing strategy will have the same safety profile.

Why Does Patient Selection Matter?

The patient's medical history should be assessed before treatment.

Particular attention may be required for patients with disorders affecting neuromuscular transmission or pre-existing weakness because the pharmacologic action of BoNT-A occurs at cholinergic nerve terminals.

Concomitant medicines may also be relevant. Drugs that interfere with neuromuscular transmission can potentially modify the effect of botulinum toxin.

Pregnancy, breastfeeding, infection at the intended injection site, previous reactions to product components and other clinical factors may also require specific consideration depending on the product label.

The exact list of contraindications and precautions should always be checked against the current locally approved product information.

What Is the Difference Between a Contraindication and a Precaution?

A contraindication describes a situation in which the product should not be used according to the approved labeling.

A warning or precaution identifies a circumstance requiring particular attention, risk assessment, monitoring or clinical judgment.

These terms should not be used interchangeably.

Because the wording can differ by product and jurisdiction, a general BoNT-A article should not replace the current label with a universal contraindication list.

Does Previous Botulinum Toxin Treatment Matter?

Previous treatment can be relevant for several reasons.

A clinician may need to know:

• which product was previously used;

• the dose;

• injection sites;

• timing of the previous treatment;

• clinical response;

• adverse effects; and

• whether response has changed over repeated treatments.

Repeated exposure also relates to the separate issue of immunogenicity and neutralizing antibodies, which is addressed in BW-10.

Previous treatment history therefore contributes both to safety assessment and interpretation of treatment response.

What Do Neuronox Clinical Trials Add to the Safety Evidence?

Neuronox has published randomized comparative clinical evidence in four distinct settings:

1. moderate-to-severe glabellar lines;

2. essential blepharospasm;

3. cerebral-palsy-associated spastic equinus; and

4. post-stroke upper-limb spasticity. [3–6]

Importantly, these studies assessed safety alongside efficacy.

This gives Neuronox product-specific clinical safety data, rather than relying only on class-level BoNT-A information.

However, the studies involve different populations, doses, muscles and follow-up periods, so their adverse-event percentages should not be pooled into one universal “Neuronox safety rate.”

What Did the Neuronox Glabellar Trial Report?

The randomized, double-blind, active-controlled Phase III glabellar study randomized 314 adults with moderate-to-severe glabellar lines. [3]

The publication reported that both NBoNT and the active comparator were well tolerated and that no serious adverse effects were observed with either toxin during the study.

This provides product-specific aesthetic safety information for Neuronox under the protocol studied.

It does not establish that serious adverse events are impossible or that the same safety findings apply to every indication or treatment technique.

What Did the Essential Blepharospasm Trial Report?

The randomized comparative essential blepharospasm study included 60 patients in the ITT population. [4]

Adverse effects were reported in:

Meditoxin/Neuronox: 16.1%

Botox: 27.6%.

The between-group difference was not statistically significant.

Reported Meditoxin adverse effects included ptosis, foreign-body sensation and irritation, and the publication described adverse effects as mild and short-lived.

No serious adverse events were reported in either group. [4]

The lower numerical event rate therefore should not be interpreted as evidence that Neuronox was safer.

What Did the Cerebral-Palsy Trial Report?

The multicentre trial included 119 children in the ITT population. [5]

A total of 34 adverse events occurred in 18 children.

In the Neuronox group, nine children experienced 15 events.

In the BOTOX group, nine children experienced 19 events.

The frequency of adverse events did not differ significantly between groups (p=0.97).

Twenty-six events were classified as mild and eight as moderate, with no event classified as severe. [5]

This provides product-specific pediatric therapeutic safety data under the conditions of that trial.

What Did the Post-Stroke Trial Report?

The Phase III post-stroke upper-limb spasticity trial randomized 196 adults. [6]

Adverse events occurred in:

39 patients receiving Neuronox

and

41 patients receiving BOTOX.

There was no significant between-group difference (p=0.7713).

Potential treatment-related adverse drug reactions were reported in four Neuronox patients and eight BOTOX patients, again without a statistically significant difference.

Serious adverse events occurred in both groups. The investigators did not identify the serious events in the Neuronox group as treatment-related. [6]

These findings should be reported in full rather than reduced to a general statement that the product was “safe.”

What Pattern Emerges from the Neuronox Evidence?

Across the four randomized comparative studies, Neuronox accumulated product-specific safety observations in both aesthetic and therapeutic populations. [3–6]

The studies did not demonstrate a consistent statistically significant safety disadvantage of Neuronox relative to the active comparators under the studied protocols.

At the same time, these trials do not establish that Neuronox is risk-free, safer than all other products or associated with one universal adverse-event rate.

The appropriate evidence-based statement is:

Neuronox has published randomized comparative trials in which safety outcomes were prospectively assessed alongside efficacy, with study-specific findings that should be interpreted within each trial's population and protocol.

Does “No Serious Adverse Events” Mean a Product Cannot Cause Serious Harm?

No.

A clinical trial can report no serious treatment-related adverse events and still be unable to rule out rare events.

The ability of a study to detect uncommon complications depends on sample size, duration of follow-up and the population studied.

This is one reason post-marketing surveillance and current regulatory labeling remain important even when randomized trials show favorable tolerability.

Why Should Current Product Information Be Checked?

Clinical papers answer research questions.

Product labeling serves a different purpose.

Current locally approved product information defines regulatory information such as:

• approved indications;

• contraindications;

• warnings and precautions;

• recommended administration;

• product-specific dosing;

• interactions;

• adverse reactions;

• storage; and

• other risk-management information.

Published clinical evidence should complement, not replace, this information.

Bottom Line

Botulinum toxin type A has substantial clinical safety experience, but safety is context-dependent rather than absolute.

Adverse effects may result from the injection procedure, the intended pharmacologic effect, unwanted effects on nearby muscles or clinically important effects beyond the intended target.

Risk depends on the specific product, indication, dose, anatomy, injection technique, patient characteristics and concomitant medications.

For Neuronox, randomized comparative trials have prospectively evaluated safety in glabellar lines, essential blepharospasm, cerebral-palsy-associated spastic equinus and post-stroke upper-limb spasticity. [3–6]

These studies provide meaningful product-specific safety evidence, but they do not justify claims that Neuronox is risk-free or universally safer than other BoNT-A products.

The most defensible approach is to combine product-specific clinical evidence with careful patient selection, appropriate administration and the current locally approved product information.

References

1. Cavallini M, Cirillo P, Fundarò SP, et al. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg. 2014;40(5):525–536. doi:10.1111/dsu.12463. PMID:24575858.

2. Jia Z, Lu H, Yang X, et al. Adverse events of botulinum toxin type A in facial rejuvenation: a systematic review and meta-analysis. Aesthetic Plast Surg. 2016;40(5):769–777. doi:10.1007/s00266-016-0682-1.

3. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. PMID:23301821.

4. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137. PMID:19794937.

5. Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x. PMID:21087238.

6. Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, Bang MS. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633. PMID:26030192.

7. NEURONOX (Botulinum toxin Type A) Thai Product Information. Revised April 3, 2023.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.